Activated G(s) signaling in osteoblastic cells alters the hematopoietic stem cell niche in mice

Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco, San Francisco, CA
Blood (Impact Factor: 9.78). 08/2012; 120(17):3425-35. DOI: 10.1182/blood-2011-11-395418
Source: PubMed

ABSTRACT Adult hematopoiesis occurs primarily in the BM space where hematopoietic cells interact with stromal niche cells. Despite this close association, little is known about the specific roles of osteoblastic lineage cells (OBCs) in maintaining hematopoietic stem cells (HSCs), and how conditions affecting bone formation influence HSC function. Here we use a transgenic mouse model with the ColI(2.3) promoter driving a ligand-independent, constitutively active 5HT4 serotonin receptor (Rs1) to address how the massive increase in trabecular bone formation resulting from increased G(s) signaling in OBCs impacts HSC function and blood production. Rs1 mice display fibrous dysplasia, BM aplasia, progressive loss of HSC numbers, and impaired megakaryocyte/erythrocyte development with defective recovery after hematopoietic injury. These hematopoietic defects develop without compensatory extramedullary hematopoiesis, and the loss of HSCs occurs despite a paradoxical expansion of stromal niche cells with putative HSC-supportive activity (ie, endothelial, mesenchymal, and osteoblastic cells). However, Rs1-expressing OBCs show decreased expression of key HSC-supportive factors and impaired ability to maintain HSCs. Our findings indicate that long-term activation of G(s) signaling in OBCs leads to contextual changes in the BM niche that adversely affect HSC maintenance and blood homeostasis.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Hematopoiesis in vertebrates is sustained over the duration of an organism's lifetime due to strict regulation of the highly hierarchical hematopoietic system, where a few immature hematopoietic stem cells continuously regenerate the entire blood supply, which is constantly being replaced. While HSCs self-regulate through cell-autonomous processes, they also receive a variety of signals from their microenvironment or niche. Within the microenvironment, HSCs are regulated through both cell-cell interactions and secreted signals, including hormones. HSCs at the apex of the blood supply integrate these signals in order produce progeny to support hematopoiesis, while simultaneously maintaining a stem cell pool. In the past 10 years advances in genetic models and flow cytometry have provided the tools to test how the microenvironment regulates HSCs. This review is organized in three main parts and will focus on cellular components of the HSC niche which are potential targets for hormonal signals, then review critical regulatory signals in the HSC niche and finally highlight the emerging role of hormonal and paracrine signals in the bone marrow.
    Molecular Endocrinology 08/2014; DOI:10.1210/me.2014-1079 · 4.20 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Though discovered later than osteoblastic niche, vascular niche has been regarded as an alternative indispensable niche operating regulation on hematopoietic stem cells (HSCs). As significant progresses gained on this type niche, it is gradually clear that the main work of vascular niche is undertaking to support hematopoiesis. However, compared to what have been defined in the mechanisms through which the osteoblastic niche regulates hematopoiesis, we know less in vascular niche. In this review, based on research data hitherto we will focus on component foundation and various functions of vascular niche that guarantee the normal hematopoiesis process within bone marrow microenvironments. And the possible pathways raised by various research results through which this environment undergoes its function will be discussed as well.
    04/2014; 2014:128436. DOI:10.1155/2014/128436
  • [Show abstract] [Hide abstract]
    ABSTRACT: Here we show that SHIP1 is required for the efficient development of osteoblasts from MSC such that bone growth and density are reduced in mice that lack SHIP1 expression in MSC. We find that SHIP1 promotes the osteogenic output of MSC by limiting activation of the PI3K/Akt/βcatenin pathway required for induction of the MSC stemness factor Id2. In parallel, we demonstrate that mice with myeloid-restricted ablation of SHIP1, including osteoclasts, show no reduction in bone mass or density. Hence, diminished bone mass and density in the SHIP1-deficient mice results from SHIP-deficiency in MSC and osteolineage progenitors. Intriguingly, mice with a SHIP-deficient MSC compartment also exhibit decreased osteoclast numbers. In agreement with our genetic findings we also show that treatment of mice with a SHIP1 inhibitor (SHIPi) significantly reduces bone mass. These findings demonstrate a novel role for SHIP1 in MSC fate determination and bone growth. Further, SHIPi may represent a novel therapeutic approach to limit bone development in osteopetrotic and sclerotic bone diseases.
    Stem Cells and Development 05/2014; DOI:10.1089/scd.2014.0122 · 4.20 Impact Factor

Full-text (2 Sources)

Available from
Aug 19, 2014